Moderately to severely active crohn's disease clinical trials
Other conditions
34 trials are recruiting, according to ClinicalTrials.gov.
Checked against the registry on 5 October 2026. Listing a trial here is not a recommendation; taking part is voluntary and each study team decides who is eligible.
VECTORS - A Study to Evaluate Transmural Healing as a Treatment Target in Crohn's Disease
Ages 18 Years to 80 Years · 60 sites · Alimentiv Inc.
Details and how to check if you qualify · NCT06257706 on ClinicalTrials.gov
A Study of SL-325 in Crohn's Disease Patients
Ages 18 Years to 80 Years · 0 sites · Shattuck Labs, Inc.
Treatment of Chinese Adult Subjects With Moderate to Severe Crohn's Disease With Tabellvi®
Ages 18 Years to 70 Years · 7 sites · Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
A Study to Assess the Pharmacokinetics, Effectiveness and Safety of Afimkibart for Induction and Maintenance Therapy in Children With Moderately to Severely Active Crohn's Disease
Ages 2 Years to 17 Years · 14 sites · Hoffmann-La Roche
A Clinical Trial of Taibowei® Adalimumab Injection in the Treatment of Chinese Pediatric Patients With Moderately to Severely Active Crohn's Disease
Ages 6 Years to 17 Years · 1 site · Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Study of Advanced Therapies for the Treatment of Adult Participants With Moderately to Severely Active Crohn's Disease or Ulcerative Colitis
Ages 18 Years to 75 Years · 56 sites · AbbVie
A Phase II Study of H021 Enteric-coated Tablets for Moderately to Severely Active Crohn's Disease
Ages 18 Years to 75 Years · 24 sites · Jiangsu Carephar Pharmaceutical Co., Ltd.
A Study of JNJ-78934804 in Participants With Moderately to Severely Active Crohn's Disease
Ages 18 Years to no maximum · 142 sites · Janssen Research & Development, LLC
A Master Protocol (IIBD): A Study of Multiple Drugs in Adults With Ulcerative Colitis or Crohn's Disease
Ages 18 Years to 80 Years · 69 sites · Eli Lilly and Company
A Study of LY4395089 and Mirikizumab (LY3074828) Given Together and Mirikizumab (Alone) in Adults With Crohn's Disease
Ages 18 Years to 80 Years · 69 sites · Eli Lilly and Company
A Study of Guselkumab Versus Risankizumab in Participants With Moderately to Severely Active Crohn's Disease
Ages 18 Years to no maximum · 158 sites · Janssen Research & Development, LLC
A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
Ages 16 Years to 80 Years · 90 sites · Sanofi
A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease
Ages 18 Years to no maximum · 362 sites · Janssen Research & Development, LLC
An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
Ages 16 Years to 80 Years · 432 sites · Sanofi
Clinical Study of the Efficacy, Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of BCD-261 in Subjects With Moderate to Severe Active Crohn's Disease
Ages 18 Years to 75 Years · 20 sites · Biocad
Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight
Ages 18 Years to 70 Years · 183 sites · Eli Lilly and Company
A Continuation Study of TAK-279 in Adults With Ulcerative Colitis (UC) and Crohn's Disease (CD)
Ages 18 Years to 75 Years · 16 sites · Takeda
A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease
Ages 16 Years to 80 Years · 194 sites · Hoffmann-La Roche
A Study of Vedolizumab in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) in the Community Setting
Ages 18 Years to 80 Years · 77 sites · Takeda
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease
Ages 16 Years to 80 Years · 360 sites · Hoffmann-La Roche
Clinical Trial of TQH3906 Capsules for the Treatment of Adult Patients With Moderately to Severely Active Ulcerative Colitis or Crohn's Disease
Ages 18 Years to 75 Years · 30 sites · Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
A Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis or Crohn's Disease
Ages 2 Years to 17 Years · 29 sites · Takeda
A Study of Vedolizumab With and Without Upadacitinib in Adults With Crohn's Disease
Ages 18 Years to 65 Years · 112 sites · Takeda
Efficacy and Safety of Obefazimod in Subjects With Moderately to Severely Active Crohn's Disease
Ages 18 Years to 75 Years · 149 sites · Abivax S.A.
Crohn's Disease: Efficacy, Safety, and Pharmacokinetics of Upadacitinib in Pediatric Subjects With Moderately to Severely Active Crohn's Disease
Ages 2 Years to 17 Years · 81 sites · AbbVie
A Phase 2 Study to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn's Disease
Ages 18 Years to 85 Years · 223 sites · Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company)
A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)
Ages 16 Years to 80 Years · 448 sites · Merck Sharp & Dohme LLC
A Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Crohn's Disease
Ages 2 Years to 17 Years · 55 sites · Janssen Research & Development, LLC
A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease
Ages 18 Years to 75 Years · 195 sites · Takeda
A Study to Assess Adverse Events, Change in Disease Activity, and How Intravenous and Subcutaneous Risankizumab Moves Through the Body of Pediatric Participants With Moderately to Severely Active Crohn's Disease
Ages 2 Years to 17 Years · 80 sites · AbbVie
PATHFINDER: Evaluating the Optimal First-Line Treatment Strategy for Moderate-to-Severely Active Ileal-dominant Crohn's Disease
Ages 18 Years to no maximum · 16 sites · University of Calgary
An Observational Study to Assess Change in Disease Activity and Adverse Events in Adolescent and Adult Participants With Moderate to Severe Active Crohn's Disease (CD) in Japan
Ages 15 Years to no maximum · 104 sites · AbbVie
A Study of Vedolizumab in Adult Participants With Moderate to Severe Crohn's Disease
Ages 18 Years to 80 Years · 31 sites · Takeda
A Study of Vedolizumab in Children and Teenagers With Moderate to Severe Crohn's Disease (CD)
Ages 2 Years to 17 Years · 80 sites · Takeda
More: Acne clinical trials · Alzheimer’s disease and related dementias clinical trials · Cannabis use disorder clinical trials · Chronic hives (chronic urticaria) clinical trials · COPD (chronic obstructive pulmonary disease) clinical trials · Depression (major depressive disorder) clinical trials
